The Journal of Pediatrics
Volume 151, Issue 4 , Pages 374-377 , October 2007

Seroprevalence of Herpes Simplex Virus Type 1 in Children in the United States

  • Fujie Xu, MD, PhD

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationReprint request: Fujie Xu, MD, PhD, Mailstop E-02, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333.
    • ,
  • Francis K. Lee, PhD

      Affiliations

    • Department of Pediatrics, Infectious Disease, and Immunology, Emory University School of Medicine, Atlanta, GA
    • ,
  • Rhoda A. Morrow, PhD

      Affiliations

    • Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, WA
    • ,
  • Maya R. Sternberg, PhD

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Kristina E. Luther, MPH

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Gary Dubin, MD

      Affiliations

    • GlaxoSmithKline, Prophylactic Vaccines, King of Prussia, PA.
    • ,
  • Lauri E. Markowitz, MD

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA

Received 26 December 2006 ,Revised 5 April 2007 ,Accepted 27 April 2007.

References 

  1. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186:S3–S28
  2. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19–36
  3. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses 1 and 2. In:  Evans AS,  Kaslow R editor. Viral Infections of Humans: Epidemiology and Control. 4th edition. New York: Plenum; 1997;p. 419–454
  4. Shoji H, Azuma K, Nishimura Y, Fujimoto H, Sugita Y, Eizuru Y. Acute viral encephalitis: the recent progress. Intern Med. 2002;41:420–428
  5. Pepose JS. Herpes simplex virus diseases: anterior segment of the eye. In:  Pepose JS,  Holland GN,  Wilhelmus KR editor. Ocular Infection and Immunity. St Louis: Mosby; 1996;p. 905–932
  6. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339:300–306
  7. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex: incidence in Rochester, Minnesota, 1950 through 1982. Arch Ophthalmol. 1989;107:1155–1159
  8. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, et al. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections). Pediatrics. 2001;108:230–238
  9. Lowhagen GB, Tunback P, Andersson K, Bergstrom T, Johannisson G. First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect. 2000;76:179–182
  10. Nilsen A, Myremel H. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand. 2000;79:693–696
  11. Tran T, Druce JD, Catton MC, Kelly H, Birch CJ. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect. 2004;80:277–279
  12. Ribes JA, Steele AD, Seabolt JP, Baker DJ. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol. 2001;39:3321–3325
  13. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003;30:797–800
  14. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. National trends in herpes simplex virus type 1 and type 2 in the United States: data from the National Health and Nutrition Examination Survey (NHANES). JAMA. 2006;296:964–973
  15. Schillinger JA, Xu F, Sternberg MR, Armstrong GL, Lee FK, Nahmias AJ, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis. 2004;31:753–760
  16. Xu F, Schillinger JA, Sternberg MR, Johnson RE, Lee FK, Nahmias AJ, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis. 2002;185:1019–1024
  17. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2 (Chiron HSV Vaccine Study Group). N Eng J Med. 1999;341:1432–1438
  18. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. GlaxoSmithKline Herpes Vaccine Efficacy Study Group (Glycoprotein-D–adjuvant vaccine to prevent genital herpes). N Engl J Med. 2002;347:1652–1661
  19. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (Vital and Health Statistics series 1, no 32). Washington, DC: US Government Printing Office; 1994;
  20. National Health and Nutrition Examination Surveys. www.cdc.gov/nchs/nhanes.htm. Accessed May 31, 2007.
  21. Lee FK, Pereira L, Griffin C, Reid E, Nahmias A. A novel glycoprotein (gG-1) for detection of herpes simplex virus–specific antibodies. J Virol Methods. 1986;14:111–118
  22. Ashley RL, Militoni J, Lee FK, Nahmias AJ, Corey L. Comparison of western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus type 1 and type 2 in human sera. J Clin Microbiol. 1988;26:662–667
  23. Leach CT, Ashley RL, Baillargeon J, Jenson HB. Performance of two commercial glycoprotein G-based enzyme immunoassays for detecting antibodies to herpes simplex viruses 1 and 2 in children and young adolescents. Clin Diagn Lab Immunol. 2002;9:1124–1125
  24. Ashley RL. Sorting out the new HSV type-specific antibody tests. Sex Transm Infect. 2001;77:232–237
  25. Elandt-Johnson RC, Johnson NL. In: Survival Models and Data Analyses. New York: Wiley; 1980;p. 69–71
  26. Schenker N, Gentleman JF. On judging the significance of differences by examining the overlap between confidence intervals. Am Statistician. 2001;55:182–186
  27. Mohadjer L, Montaquila JM, Waksberg J, Bell B, James P, Flores-Cervantes I, et al. National Health and Nutrition Examination Survey III: Weighting and Estimation Methodology. Hyattsville, MD: National Center for Health Statistics; 1996;
  28. National Center for Health Statistics. NHANES Analytic Guidelines. Atlanta, GA: US Department of Health and Human Services, National Center for Health Statistics; 2004;Available at http://www.cdc.gov/nchs/data/nhanes/nhanes_general_guidelines_june_04.pdf. Accessed May 31, 2007.

 Supported by funding from the Centers for Disease Control and Prevention. GlaxoSmithKline Biologicals, Inc. provided funding for serologic testing.

 No reprints are available from the authors.

 The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

PII: S0022-3476(07)00442-8

doi: 10.1016/j.jpeds.2007.04.065

The Journal of Pediatrics
Volume 151, Issue 4 , Pages 374-377 , October 2007

Article Tools

* Image Usage & Resolution